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Introduction: The primary target in the treatment of hypercholesterolemia is
often to lower low-density lipoprotein (LDL) cholesterol, rather than improve
clinical outcomes. Despite the wide use of lipid-modifying drugs, considerable
cardiovascular mortality and morbidity remains with this disease. Hypercholes-
terolemia plays a key role in the development andprogression of atherosclerosis
and can lead to cardiac heart disease.
Areas covered: The purpose of this review is to determine whether ezetimibe
has proven clinical benefits; it discusses the clinical trials of simvastatin and
ezetimibe alone and in combination.
Expert opinion: Simvastatin has been clearly shown to decrease LDL-cholesterol,
which is associated with the slowing of atherosclerosis and a reduction in
cardiovascular morbidity and mortality. Ezetimibe alone or in the presence of
simvastatin lowers LDL-cholesterol. However, ezetimibe alone or in the pres-
ence of simvastatin has not been shown to have any irrefutable beneficial
effects on atherosclerosis or cardiovascular morbidity and mortality. Thus,
until/unless the use of ezetimibe is clearly shown to improve clinical outcomes,
its use should be largely restricted to clinical trials investigating clinical
outcomes and should not be used routinely in everyday practice.
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1. Introduction
Despite the wide use of lipid-modifying drugs, considerable cardiovascular mortality
and morbidity remains. Hypercholesterolemia has a key role in the development and
progression of atherosclerosis, and leads to cardiac heart disease. The primary target
in the treatment of hypercholesterolemia is lowering low-density lipoprotein (LDL)
cholesterol optimally, which according to the National Cholesterol Education ATP
III guidelines is < 100 mg/dl (2.59 mmol/l) [1]. The medicines most commonly used
initially to lower LDL-cholesterol are the statins [1]. If the statins are unsuccessful at
achieving the 2.59 mmol level of LDL-cholesterol, one approach is to increase
the dose of the statin, but this also increases the likelihood of adverse effects with
the statins [2]. Another problem with increasing the dose of the statin is, although
it further decreases the levels of LDL-cholesterol, this is often not enough to reach
optimal levels of LDL-cholesterol [3].
An alternative approach, when statins do not lower LDL-cholesterol optimally, is
to add another LDL-cholesterol-lowering medicine to the statin, and one that is
increasingly used is ezetimibe. Ezetimibe inhibits the Niemann--Pick-like 1 enterocyte
receptor to inhibit the absorption of cholesterol, and this leads to the lowering of
plasma LDL-cholesterol levels [4].
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When new lipid-lowering drugs are being developed, as was
the case with ezetimibe, their ability to lower LDL-cholesterol
is initially investigated, as a surrogate for clinical outcomes.
Ezetimibe lowers LDL-cholesterol. Many studies seem to accept
LDL-cholesterol lowering as having a direct relationship to
clinical benefit. The evidence for this comes from surgical and
medicinal studies. In the surgical study, partial ileal bypass
was shown to reduce LDL-cholesterol levels, and cardiovascular
mortality and morbidity in subject who had experienced a heart
attack [5]. The medicinal evidence for this comes predominantly
from studies with statins, the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors, but has also been shown for the
sequestrant cholestyramine resin [6]. It seems to have been
assumed by many that by lowering LDL-cholesterol, ezetimibe
will have a positive effect on clinical outcomes, and this assump-
tion underlies the increasing use of ezetimibe, especially in com-
bination with simvastatin (e.g., [7,8]). However, to confirm that
lowering LDL-cholesterol translates into reduced cardiovascular
events, clinical outcome studies with individual medicines
are needed.
This review challenges the assumption that lowering
LDL-cholesterol with ezetimibe alone or in combination with
simvastatin leads to improved clinical outcomes. In the first
part of the review, the compelling evidence that lowering
LDL-cholesterol with simvastatin is associated with improved
clinical outcomes is discussed. LDL-cholesterol lowering and
clinical outcome studies have been undertaken with ezetimibe
but these do not show a clear association between lowering
LDL-cholesterol and improved clinical outcomes, and the
studies with ezetimibe alone or in combination with simvastatin
are discussed in the second and third part of the review,
respectively. Given that there is no clear-cut evidence that ezeti-
mibe alone has a beneficial effect on clinical outcomes in hyper-
cholesterolemia, the author argues in the expert opinion section
that ezetimibe should not be used widely until clinical outcome
studies have demonstrated benefits alone, or in the presence
of simvastatin.
2. Simvastatin and clinical end points
2.1 High-risk subjects
The effects of simvastatin on LDL-cholesterol levels and clinical
outcomes are summarised in Table 1. The Scandinavian Simva-
statin Survival Study (4S) was the first study to show that cho-
lesterol lowering with a statin decreased total and cardiovascular
mortality [9]. The subjects enrolled had coronary artery disease,
and a mean LDL-cholesterol of 4.86 mmol/l [9], which is a high
average. The reduction in major coronary events in 4S was
highly correlated with on-treatment levels and changes from
baseline in total and LDL-cholesterol. There was less of a
correlation with high-density lipoprotein (HDL)-cholesterol
and no clear relationship with triglycerides [10].
Simvastatin yields continued survival benefit. Adding the
deaths in a 2-year follow-up period to the 4S, to those occur-
ring during the original trial, the total was 353 (15.9%) and
256 (11.5%) deaths in the groups originally randomised to
placebo and simvastatin, respectively [11].
Post hoc analysis of 4S showed that simvastatin reduced the
risk of the combined end point of stroke and transient
ischaemic attack and also reduced the risk of new or worsening
intermittent claudication by 38% (Table 1) [12]. Subjects with
diabetes mellitus have a marked increase in coronary heart dis-
ease events relative to those without diabetes, and using the 4S
database, simvastatin has been shown to improve this prognosis
(Table 1) [13]. In subjects with mild chronic renal insufficiency,
simvastatin was also beneficial on cardiovascular outcomes
(Table 1) [14]. In 4S, there were 409 subjects with moderate
chronic renal insufficiency, and in these subjects to odds of
receiving a ‡ 25% reduction in glomerular filtration rate were
lower with simvastatin (2.5%) than with placebo (6.2%) [15].
Many of the benefits initially observed in the 4S trial were
confirmed in the MRC/BHF Heart Protection Study over
5 years (Table 1) [16]. As this was a very large study, it was
able to confirm the benefits of simvastatin (40 mg/day) on
subcategories (e.g., patients without coronary disease but
with cerebrovascular or peripheral artery disease, and even
those with LDL-cholesterol below 3.00 mmol/l). It was con-
cluded that the benefit of simvastatin depended chiefly on
the individuals’ overall risk of major vascular events, rather
than on blood lipid concentrations alone [16]. Subsequently,
in the Heart Protection Study, simvastatin was shown to
reduce ischaemic, but not haemorrhagic stroke, and to reduce
transient ischaemic events (Table 1 [17]). Simvastatin also
decreased major coronary events to a greater extent in subjects
in the Heart Protection Study with diabetes than without
diabetes [18], and decreased the rate of first peripheral event
Article highlights.
. It is well established that simvastatin lowers low-density
lipoprotein (LDL)-cholesterol, which is associated with
the slowing of atherosclerosis and reduction in
cardiovascular morbidity and mortality.
. Ezetimibe alone or in the presence of simvastatin lowers
LDL-cholesterol, but may increase the atherogenic
small-dense LDL-cholesterol.
. Ezetimibe alone or in the presence of simvastatin has
not been shown to slow atherosclerosis, and may even
increase it.
. Ezetimibe alone or in the presence of simvastatin has
not been shown to have an effect on cardiovascular
morbidity and mortality.
. IMPROVE-IT has been set up to determine the clinical
outcomes with ezetimibe in the presence of simvastatin,
but the results of IMPROVE-IT will not be known till
2015, and because of the large number of primary end
points, may go on for longer, or be inconclusive.
. Until/unless ezetimibe is shown to improve clinical
outcomes, its use should be largely restricted to clinical
trials investigating clinical outcomes and should not be
used routinely in everyday practice.
This box summarises key points contained in the article.
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to a greater extent in those with peripheral vascular disease
than without [19] (Table 1). In subjects with peripheral arterial
disease, simvastatin also increases the treadmill time to the
onset of intermittent claudication [20].
2.2 Comparing simvastatin doses
Early intensive simvastatin (40 mg for a month, followed by
80 mg) and delayed conservative simvastatin treatment
(placebo for 4 months, followed by 20 mg) has been
compared in 4497 subjects with acute coronary syndromes
(non-ST-elevation acute coronary syndrome or ST-elevation
myocardial infarction). The primary end point was a compo-
site of cardiovascular death, non-fatal myocardial infarction,
readmission for acute coronary syndrome and stroke, and
after 1 year, there was no difference between the early inten-
sive (14.4%), and delayed conservative simvastatin treatment
(16.7%). Individual item analysis showed a significant
(p = 0.5) lower level of cardiovascular death with the intensive
than conservative treatment [21].
Recently, a low dose of simvastatin, 20 mg, has been com-
pared with a high dose, 80 mg, in 12,064 subjects who had
survived a myocardial infarction by the SEARCH (Study of
the Effectiveness of Additional Reductions in Cholesterol
and Homocysteine) collaborative group [22]. After 6.7 years,
there was no significant difference in major vascular events
(coronary death, myocardial infarction or coronary revascula-
risation) between the two doses [22]. There was also no signi-
ficant difference between the two doses of simvastatin on
the incidence of stroke, non-fatal stroke, transient ischaemic
attacks or admission to hospital for stable or unstable
angina [22]. As 40 mg is the more usual standard dose of
simvastatin, it is not clear, why 20 mg simvastatin was chosen
in this study. The finding of this study with low- and
high-dose simvastatin differs from the results obtained by
Table 1. LDL-cholesterol lowering with simvastatin and clinical outcomes.
Trial with simvastatin LDL-cholesterol lowering Clinical outcomes Ref.
The 4S trial: 4444 subjects with coronary
artery disease (previous myocardial infarction
or in 20% angina); simvastatin 20 -- 40 mg,
vs placebo for 5.4 years
From 4.84 mmol/l by 35% Reduced death (by 33%),
cardiovascular death (40%), risk of
undergoing revascularisation
procedures (34%)
[9]
4S Reduced the combined end point
of stroke and transient ischaemic
attack (28%), and of intermittent
claudication (36%)
[12]
Subjects in 4S with normal and impaired
fasting glucose, and diabetes
Subgroup analysis showed reduced
major coronary events, and
revascularisations in diabetes, and
reduced coronary deaths, major
coronary events, revascularisations
in impaired fasting glucose and
diabetes
[13]
2314 subjects in 4S with mild chronic renal
insufficiency
Reduced all-cause mortality, rates
of major coronary events, and
coronary revascularisation
[14]
MRC/BHF Heart Protection Study: 20,536
high-risk subjects; simvastatin 40 mg vs
placebo for 5 years
From 3.4 mmol/l by 1.3 (38%),
0.9 (27%) and 0.7 mmol (21%),
after 1, 3 and 5 years,
respectively
Reduced all-cause mortality (14%),
coronary death rate (18%),
non-fatal myocardial infarction
(38%), non-fatal or fatal stroke
(25%), any revascularisation
process (22%)
[16]
MRC/BHF Heart Protection Study Reduction is ischaemic (28%) but
not haemorrhagic stroke, and
reduction in transient ischaemic
events (17%)
[17]
MRC/BHF Heart Protection Study: Subjects
with diabetes vs those without
Reductions in the first event rate
for major coronary events, for
strokes, and for revascularisations
[18]
MRC/BHF Heart Protection Study: subjects
with peripheral arterial disease vs those
without
Reduction in first peripheral
vascular event
[19]
LDL: Low-density lipoprotein.
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the Cholesterol Treatment Trials’ (CTT) Collaborative, when
they compared low- and high-dose/potency statins. One pos-
sible reason for this is that the difference in LDL lowering was
smaller (0.35 mmol) with low- and high-dose simvastatin in
SEARCH than the 0.51 mmol with intensive versus less
intensive treatment with statins [23].
2.3 Comparing simvastatin with other statins
Simvastatin has been comparedwith pravastatin and atorvastatin,
each at their standard dose, and it was shown that there was no
difference in reducing fatal coronary heart disease, non-fatal
myocardial infarction and fatal and non-fatal stroke [24].
Subjects with heterozygous familial hypercholesterolemia are
at increased risk of coronary artery disease. Simvastatin (40 mg)
was compared with atorvastatin (80 mg) in 325 subjects
with familial hypercholesterolemia in the ASAP trial. LDL-
cholesterol was loweredmore with atorvastatin than simvastatin.
Over 2 years, the intima media thickness of the carotid artery
increased in the simvastatin group, but decreased in the atorvas-
tatin group. The change on intima media thickness correlated
with the percentage LDL-cholesterol lowering [25].
Simvastatin (20 mg) was compared with high-dose atorva-
statin (80 mg) in 8888 subjects after myocardial infarction in
the IDEAL (Incremental Decrease in End points through
Aggressive Lipid lowering) study. After 24 weeks of follow-up,
21% in the simvastatin group had their dose increased to
40 mg. The primary outcome was major coronary events (coro-
nary death, non-fatal myocardial infarction, cardiac arrest with
resuscitation), and this was not significantly different (p = 0.07)
for the simvastatin and atorvastatin groups. However, there
was an added benefit with atorvastatin at reducing non-fatal
myocardial infarction, and coronary revascularisation [26].
In 2005, the CTT Collaboration combined 14 randomised
trials with statins including simvastatin, and concluded that
statin therapy reduced the 5-year incidence of major coronary
events, coronary revascularisation and stroke by about one-
fifth per mmol/l reduction in LDL-cholesterol [27]. There
were similar findings in 2009, when seven more statin trials
were included [28].
In 2010, the CTT Collaboration, used meta-analysis to
compare standard statin therapy (e.g., 20 -- 40 mg simvastatin)
to regimens involving higher doses, or the more potent statins
(e.g., 40 -- 80 mg atorvastatin, 10 -- 20 mg rosuvastatin). The
meta-analysis involved 170,000 participants from 26 rando-
mised trials. In this study, the lowering of LDL-cholesterol
was 0.51 mmol/l more, with the intensive, than less intensive
treatment. In this study, the more intensive therapy signifi-
cantly decreased the major vascular events (coronary death,
non-fatal myocardial infarction, coronary revascularisation
and ischaemic stroke) when they were combined or assessed
individually [23].
2.4 Simvastatin in vascular remodelling
TheMulticenter Anti-Atheroma Study (MAAS) of 381 patients
with coronary artery disease showed that simvastatin slowed the
progression of diffuse and focal coronary atherosclerosis. There
were also less coronary angioplasty or revascularizations in the
simvastatin than placebo group [29].
In the Coronary Intervention Study (CIS), the effect of a
higher dose of simvastatin (40 mg/day) on coronary angiogra-
phy was evaluated over 2.3 years [30]. In this group of 254 men
with hypercholesterolemia and coronary artery disease, there
was less of a decrease in coronary diameter in the simvastatin
than placebo group [30]. Simvastatin has also been shown to
decrease, and then cause regression, in atherosclerotic lesions
in aortic or carotid artery plaques in subjects with asymptomatic
hypercholesterolemia [31,32]. In subjects with familial hyper-
cholesterolemia, simvastatin 80 mg reduced the primary end
point, which was the change in the combined intima--media
thickening of the carotid and femoral artery [33].
3. Ezetimibe alone, LDL-cholesterol
and clinical end points
In 243 subjects with primary hypercholesterolemia (LDL-
cholesterol, ~ 4.40 mmol/l), ezetimibe at 0.25, 1, 5 and
10 mg, reduced LDL-cholesterol in a dose-dependent manner
from 9.9 to 18.7% over 12 weeks [34]. Larger studies and
meta-analysis have confirmed the ability of ezetimibe 10 mg
to lower LDL-cholesterol by ~ 18% [35-37].
There have been few studies of ezetimibe alone on clinical
end points. One reason for this may be that a lowering of
LDL-cholesterol by 18% (~ 0.79 mmol/l) with ezetimibe
10 mg alone may not have a large effect on clinical out-
comes. In subjects with chronic heart failure, the effects of
ezetimibe 10 mg have been compared with simvastatin
10 mg, over 4 weeks on flow-dependent dilation of the
radial artery [38]. Both ezetimibe and simvastatin lowered
LDL-cholesterol by ~ 15%, but only simvastatin improved
the dilation [38]. It has been suggested that the ability of
simvastatin to improve endothelium function was due to a
pleiotropic effect of simvastatin, that is, not LDL-cholesterol
lowering [38]. Another possibility is that the benefit of
ezetimibe on lowering LDL-cholesterol on endothelium
function is offset by another action, but the benefit of sim-
vastatin on lowering LDL-cholesterol presents as improved
endothelium function.
Ezetimibe 10 mg has been compared with niacin in subjects
who had coronary heart disease or a coronary heart disease
risk, who are taking statins in the ARBITER 6-HALTS
(Arterial Biology for the Investigation of the Treatment
Effects of Reducing cholesterol 6-HDL and LDL Treatment
Strategies; Table 2) [39]. The primary end point was the
between-group change in mean carotid intima--media thick-
ness after 14 months, and there was little difference in the
carotid thickness with ezetimibe, but a significant reduction
with niacin [39]. The author postulated that actions, other
than decreasing LDL-cholesterol, counter the beneficial effect
that would be expected with LDL-cholesterol lowering with
ezetimibe [39]. The final results of the ARBITER 6-HALTS
S. A. Doggrell
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study have been reported and these confirm the findings with
the 208 subjects [40].
4. Simvastatin and ezetimibe in combination
4.1 LDL-cholesterol
Simvastatin and ezetimibe have different mechanism of actions,
and this may explain why, in combination, they have an addi-
tive effect on LDL-cholesterol. In subjects with primary hyper-
cholesterolemia, and LDL-cholesterol of 4.60 mmol/l,
simvastatin (combined for 10, 20, 40 and 80 mg) lowered
LDL-cholesterol by about 32%, and in the presence of simva-
statin (combined doses), ezetimibe lowered LDL-cholesterol
by a further 14% [41]. In another study in subjects with primary
hypercholesterolemia, and LDL-cholesterol of 4.61 mmol/l,
simvastatin (combined for 10, 20, 40 and 80 mg) lowered
LDL-cholesterol by 42%, ezetimibe by 22% and the combi-
nation of simvastatin and ezetimibe by 56% [42]. Pooled data
from 27 clinical trials, showed that when ezetimibe 10 mg
was added to a statin (simvastatin, lovastatin, pravastatin,
atorvastatin, rosuvastatin), there was a 16.1% reduction in the
levels of LDL-cholesterol [42]. The reduction with the addition
of ezetimibe was slightly greater in subjects with diabetes,
17.4%, than in subjects without diabetes [42].
The effect of combining ezetimibe with simvastatin is more
effective at decreasing LDL-cholesterol than increasing the
dose of simvastatin. Thus, in subjects with hypercholesterol-
emia, simvastatin 10, 20, 40 and 80 mg lowered LDL-
cholesterol by 27, 37, 38 and 45%, whereas adding ezetimibe
10 mg to these doses lowered LDL-cholesterol by 46, 46,
Table 2. LDL-cholesterol lowering with ezetimibe and clinical outcomes.
Trial with ezetimibe LDL-cholesterol lowering Clinical outcomes Ref.
ARBITER 6-HALTS
trial: 208 subjects with coronary
artery disease or risk, treated
with atorvastatin or simvastatin
randomised to ezetimibe 10 mg
or niacin
From 2.13 mmol/l by ~ 28% with
ezetimibe and ~ 17% by niacin
Ezetimibe had no effect on carotid
thickness, which was reduced by niacin,
and more cardiovascular adverse effects
with ezetimibe than niacin
[39]
ENHANCE study: 720 subjects
with familial
hypercholesterolemia treated
with simvastatin 80 mg or
simvastatin 80 mg/
ezetimibe 10 mg
After 24 months from 8.22 to
4.99 mmol/l with simvastatin and from
8.25 to 4.59 mmol/l with simvastatin/
ezetimibe
Intima--media thickness of coronary artery
increased similarly in both groups
[46]
VYCTOR study: 90 subjects with
high cardiovascular risk,
compared the effects of
simvastatin 40/80 mg (40 mg,
45%; 80 mg, 55%) alone with
simvastatin 20/40 (20 mg, 83%;
40 mg, 17%)
LDL-cholesterol was lowered from
3.37 to 1.17 mmol/l (2.20 mmol/l,
65%) by simvastatin, and from 3.37 to
1.14 mmol/l (2.13 mmol/l, 66%) by
the combination of simvastatin and
ezetimibe
Carotid intima thickness was reduced by
30% with simvastatin alone, and by 25%
with the combination, and this was not
significantly different
[49]
SEAS: 1873 subjects with mild-
to-moderate, asymptomatic
aortic stenosis, and the subjects
were given either simvastatin
40 mg and ezetimibe 10 mg or
placebo
With these doses of simvastatin/
ezetimibe, there was 61.3% decrease
in the levels of LDL-cholesterol
After a follow-up of 52.2 months, the
primary outcome (composite of major
cardiovascular events) had occurred in
333 subjects in the simvastatin/
ezetimibe group (35.3%) and
355 subjects in the placebo group
(38.2%).
Aortic-valve replacement was performed
by a similar percentage in the simvastatin/
ezetimibe and placebo groups (28.3 vs
29.9%)
[54]
SHARP: Initially, 9270 subjects
with moderate kidney disease
were randomised to placebo,
simvastatin and simvastatin and
ezetimibe, but after 1 year
1000 subjects randomised to
simvastatin, were re-randomised
to simvastatin/ezetimibe or
placebo
The baseline levels of LDL-cholesterol
were ~ 2.77 mmol/l, and were
lowered by ~ 1 mmol/l by the
combination of simvastatin and
ezetimibe
The primary end point was the reduction
in major atherosclerotic events (coronary
events, non-haemorrhagic stroke,
revascularisation procedure) and this
occurred in 528 of the 4650 subjects
taking simvastatin/ezetimibe (11.3%),
which was less than 619 of 4620 subjects
in the placebo group, 13.4%
[56]
The ezetimibe controversy -- can this be resolved by comparing the clinical trials
Expert Opin. Pharmacother. (2012) 13(10) 1473
Ex
pe
rt 
O
pi
n.
 P
ha
rm
ac
ot
he
r. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
58
.1
65
.1
09
.2
12
 o
n 
06
/2
3/
12
Fo
r p
er
so
na
l u
se
 o
nl
y.
56 and 58%, respectively [41]. Another study in subjects with
hypercholesterolemia showed similar results, with simvastatin
10, 20, 40 and 80 mg lowering LDL-cholesterol by 33, 34,
41 and 48%, whereas adding ezetimibe 10 mg to these doses
lowered LDL-cholesterol by 45, 52, 55 and 60%, respec-
tively [43]. Also, combining ezetimibe and simvastatin was
more effective at lowering LDL-cholesterol than increasing
the dose of atorvastatin [44] or rosuvastatin [45].
4.2 Clinical outcomes
The ENHANCE (Ezetimibe and Simvastatin in Hypercholes-
terolemia Enhances Atherosclerosis Regression) study was in
subjects with familial hypercholesterolemia, and compared a
high dose of simvastatin 80 mg with simvastatin 80 mg with
ezetimibe 10 mg (Table 2). The primary outcome measure
in ENHANCE was intima--media thickness of the carotid
artery, and this increased in both groups, and was not signi-
ficantly different with the addition of ezetimibe. One of the
possibilities considered for this result was that, LDL lowering
by a drug other than a statin, that is, ezetimibe, was not asso-
ciated with reduction in the progression of atherosclerosis, as
there were differences in the mechanisms of action of ezeti-
mibe and simvastatin, for example, the pleiotropic effects of
the statins [46]. The baseline intima--media thickness of the
carotid artery was low in ENHANCE. Thus, another sugges-
tion has been that prior use of statins by subjects in
ENHANCE had lowered the thickness of the carotid artery,
and that further treatment with either simvastatin alone or
simvastatin with ezetimibe had no further effect [47].
In another study in subjects with familial hypercholesterol-
emia, the combination of simvastatin and ezetimibe have been
compared in two groups of subjects; those with a history of
myocardial infarction and those with carotid atherosclerosis
plaques but no history of cardiovascular events [48]. As this
study does not have a group with simvastatin or ezetimibe
treatment alone, it is not possible to assess the effect of
ezetimibe alone. What the study does show is that the combi-
nation of simvastatin and ezetimibe lowers LDL-cholesterol
and reduces carotid intima--media thickness in these
subjects [48], but it does not clarify whether ezetimibe alone
reduces carotid intima--media thickness or contributes to the
effect when used in combination with simvastatin.
The VYCTOR (Vytorin on Carotid Intima--Media Thick-
ness and Overall Arterial Rigidity) study compared the effects
of simvastatin alone with simvastatin and ezetimibe 10 mg on
carotid intima--media thickening (Table 2) [49]. Carotid intima
thickness was reduced similarly by simvastatin alone, and the
combination [49]. The authors of VYCTOR study suggest that
the unusually high lowering of the LDL-cholesterol with sim-
vastatin alone may be due to good adherence by the subjects
in this trial [49], but this does not explain why there was not
an additive effect between simvastatin and ezetimibe. They
also suggest that the difference between ENHANCE and
VYCTOR are due to there being definite intima--media
thickening at baseline in VYCTOR but not ENHANCE [49].
They conclude that the dual therapy has a beneficial effect on
carotid arteries [49], but the author of this review fails to
understand this conclusion. A possibility not raised by the
authors of VYCTOR study was that the LDL lowering with
simvastatin alone was large enough to explain the results
in both groups, and that the addition of ezetimibe did not
add to this.
SANDS (Stop Atherosclerosis in Native Diabetic Study)
was set up to compare aggressive and standard treatment for
lowering LDL-cholesterol on carotid artery intima--media
thickness in subjects with diabetes [50]. SANDS used a statin
to reduce LDL-cholesterol, and if the statin alone did not
reduce the LDL-cholesterol to the required level, ezetimibe
was added to the treatment [50]. Thus, although SANDS was
not set up to compare ezetimibe/simvastatin with simvastatin
alone, the data were available for extraction. On extraction, it
was shown that there was a similar reduction in LDL-
cholesterol levels and carotid intima--media thickness in the
simvastatin and simvastatin/ezetimibe group [51]. One of the
limitations of this study was that there were only 69 subjects
taking statins/ezetimibe, compared with 154 subjects con-
trolled by statins alone in the aggressive group [51]. The author
of this review suggests that as in SANDS, the carotid intima--
media was thicker (0.81 mm) than in ENHANCE, where the
baseline intima--media thickness was 0.69 mm, there was a
greater chance of decreasing intimal thinkness [51]. However,
another interpretation is that the reduction in carotid
thickness in both groups was due to the statin alone.
The study of West et al. is the only clinical outcome study
with ezetimibe to have a clear-cut result for ezetimibe alone,
and it is a detrimental effect; ezetimibe alone leads to the pro-
gression of atherosclerosis in subjects with peripheral arterial
atherosclerosis [53]. In this study, 67 subjects with peripheral
arterial atherosclerosis were treated with simvastatin 40 mg,
ezetimibe or the combination. Atherosclerotic plaque volume
in the superficial femoral artery did not change in the simva-
statin or the simvastatin/ezetimibe group, but increased in the
ezetimibe group [53].
In the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis)
trial, it was also difficult to determine the effect of ezetimibe
alone, as the effects of combined simvastatin/ezetimibe were
compared with placebo (not simvastatin alone) (Table 2) [54].
The background to SEAS was that lipid-lowering treatment
might prevent the progression of aortic-valve stenosis
and reduce the need for aortic valve replacement, but lipid
lowering with a combination of simvastatin and ezetimibe did
not do this [54]. In SEAS, the primary outcome (composite of
major cardiovascular events) and aortic valve replacement
occurred in similar percentage in both groups [54]. When the
subjects in SEAS were divided into tertiles on the basis of seve-
rity of asymptomatic aortic stenosis, there was still no difference
in aortic valve events between those treated with simvastatin/
ezetimibe and placebo [55]. In the original SEAS, the ischemic
events (non-fatal myocardial infarction, coronary-artery bypass
grafting, percutaneous coronary intervention, hospitalisation
S. A. Doggrell
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for unstable angina, non-haemorrhagic stroke and death from
cardiovascular causes) occurred less often the simvastatin/
ezetimibe group (15.7%) than the placebo group (20.1%),
and this difference was mainly due to a decrease in coronary-
artery bypass grafting (10.8 -- 7.3%) [54]. In SEAS, cancer
occurred more often in the simvastatin/ezetimibe group
(105 subjects) than in the placebo group (70 subjects) [54]. As
cancer has not been reported as an adverse effect with simva-
statin, this suggests that the increased rate of cancer in SEAS
may be due to ezetimibe, and this is discussed further in the
commentary below.
In the recently published SHARP (Study of Heart and
Renal Protection), simvastatin/ezetimibe was again compared
with placebo, this time in subjects with moderate-to-severe
kidney disease (Table 2). The rationale for using the combina-
tion of simvastatin 20 mg with ezetimibe 10 mg is that high-
dose statins cause myopathy, particularly in subjects with
impaired renal function. The primary end point was the
reduction in major atherosclerotic events and this occurred
in less subjects taking simvastatin/ezetimibe than placebo.
This reduction was due to there being less ischaemic strokes
and coronary revascularisation with simvastatin/ezetimibe
combination, compared with placebo [55].
The authors of the SHARP study in their discussion refer
to the CTT Collaboration, which showed that lowering
LDL-cholesterol by 1 mmol/l with statins was associated
with a 20% reduction in the risk of myocardial infarction or
coronary death, stroke or coronary vascularisation [23]. In
SHARP, ezetimibe combined with simvastatin lowered
LDL-cholesterol by 0.85 mmol/l, and caused a 17% decrease
in major atherosclerotic events, which was considered to be
consistent with the results with statins alone [56]. The authors
of the SHARP study claim that adding ezetimibe to simva-
statin is equivalent of three doublings of the dose of statin
on the basis of the study of Davison et al. 2002 [41].
A retrospective cohort study has suggested that in subjects
discharged after hospitalisation for acute coronary syndromes,
the administration of ezetimibe with simvastatin may reduce
the rehospitalisation due to acute coronary syndromes, percu-
taneous transluminal coronary angioplasty and revascularisa-
tion, compared with statins alone [52]. However, the authors
of the SHARP study acknowledge that there are lots of limi-
tations to their study, including the non-matching doses of
statins between the groups with a lower average dose of statin
in the statin group than in the combination group, lack of
information on baseline LDL-cholesterol levels and the lack
of information on deaths [52].
5. Expert opinion
5.1 Simvastatin
In reviewing simvastatin (Section 2), it is clear that simvastatin
lowers LDL-cholesterol, and this lowering is associated with
beneficial clinical cardiovascular outcomes. Thus, in subjects
with coronary artery disease, simvastatin reduced cardiovascular
mortality and morbidity. However, there is some controversy
about whether increasing the lowering of LDL-cholesterol by
increasing the dose of statin, increases the benefit in outcomes.
Thus, this has not been clearly shown with simvastatin alone,
but has been shown by comparing simvastatin with the higher
potency statins at higher doses.
5.2 Effect of ezetimibe alone on LDL-cholesterol and
clinical outcomes
In reviewing the effect of ezetimibe on LDL-cholesterol
(Section 3), it is clear that ezetimibe 10 mg alone only has a
modest ability to lower LDL-cholesterol. As per SA Doggrell’s
knowledge, the highest dose of ezetimibe which has been tested
in humans is 10 mg, which is well tolerated, and has not been
shown to give a maximal effect at lowering LDL-cholesterol. If
there is a dose-related effect of ezetimibe on LDL-cholesterol, a
higher dose (say 15 or 20 mg) may give a larger decrease in
LDL-cholesterol, and this may have a beneficial effect on
clinical outcomes, but this has not been tested to date.
Many seem to have assumed that the modest ability of
ezetimibe 10 mg on LDL-cholesterol may not be large enough
for ezetimibe alone to have a beneficial effect on clinical
outcomes in coronary disease. However, this has not been
tested, and should be. Ezetimibe has a similar ability to lower
LDL-cholesterol in the presence of simvastatin, and it is has
been postulated that this will lead to an increase in clinical
improvement. This may be due to the ATP III guidelines,
that suggest that the greater the reduction in LDL-cholesterol,
the greater the reduction in cardiovascular risk [1]. The experi-
mental evidence supporting this is mainly from a meta-analysis
comparing the high potency statins with standard treatment,
and showing greater reductions in lowering LDL-cholesterol
were associated with greater beneficial cardiovascular
outcomes [23]. However, this has not been observed in the
SEARCH clinical trial by increasing the dose of simvastatin
alone [22], or conclusively by increasing the lowering of
LDL-cholesterol by adding ezetimibe to a statin.
5.3 Effect of ezetimibe in the presence of simvastatin
According to SA Doggrell’s understanding of clinical trials, it is
not ethical to deprive subjects with medical conditions of agents
that have a proven beneficial activity in that medical condition.
The statins have proven ability to reduce cardiovascular morta-
lity and morbidity in subjects with coronary artery disease.
Thus, subjects with proven coronary artery disease should
receive a statin, and when a new agent is tested, it should be
tested in the presence of the statin. Thus, in coronary artery
disease, ezetimibe should be compared with subjects who are
taking a statin. In ENHANCE, ezetimibe was compared with
placebo in subjects with familial hypercholesterolemia, and
shown to have no effect on the intima--media thickness of
the carotid artery [46]. In the commentary published with
EHHANCE, Brown and Taylor pointed out the similar popu-
lation and methodology between ENHANCE and ASAP [57].
Whereas a decrease of intima--media thickness was observed
The ezetimibe controversy -- can this be resolved by comparing the clinical trials
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with atorvastatin 80 mg in ASAP [25], for the same lowering of
LDL-cholesterol with simvastatin combined with ezetimibe in
ENHANCE, there was an increased intima--media thickness
of the carotid artery [57]. Brown and Taylor raised three possi-
bilities to explain this; first, carotid intima--media was more
advanced at baseline in ASAP [57]. Second, the subjects had
a longer history of statin treatment in ENHANCE than
ASAP [57]. Third, atorvastatin was used in ASAP whereas
simvastatin/ezetimibe was used in ENHANCE [57].
As a consequence of the lack of effect on intima--media
thickening with ezetimibe in ENHANCE, Brown and Taylor
suggested the following approach to treatment: first achieve
the levels of LDL- and HDL-cholesterol with the statins
plus drugs that have been shown to have clinical benefits
when added to statins, that is, nicotinic acid, fibrates and
bile acid sequestrants, as tolerated [57]. Only, use ezetimibe
in subjects who do not achieve the targets with the other com-
binations [57]. Even as a last resort, it seems, that ezetimibe
should not be added to statins to lower LDL-cholesterol to
such time as ezetimibe has been shown to have a beneficial
effect on clinical outcomes.
The study of West et al. is the only clinical outcome study
with ezetimibe to have a clear-cut result for ezetimibe alone,
and it is a detrimental effect; ezetimibe (in the presence of simva-
statin) leads to the progression of atherosclerosis in subjects with
peripheral arterial atherosclerosis [53]. The authors of this study
seemed to have assumed that ezetimibe was going to have a bene-
ficial effect, and that this has been halted by prior simvastatin
treatment [53]. Given that there is no prior evidence that ezeti-
mibe alone halts or reverses atherosclerosis, this seems illogical.
It is considered that the evidence should be accepted per se,
that is, in the presence of simvastatin, ezetimibe causes progres-
sion of atherosclerosis in the peripheral arterial atherosclerosis.
The study by West et al. [53] produces strong evidence for with-
drawing ezetimibe from use in practice, until clinical trials have
produced clear-cut results as to whether ezetimibe has beneficial
or detrimental effects on cardiovascular clinical outcomes.
Although LDL-cholesterol lowering is commonly used as
a surrogate for likely clinical beneficial outcomes with
lipid-modifying drugs, there is evidence that the benefit is
predominantly due to the lowering of the small dense LDL-
cholesterol [58]. Consequently, lowering of small dense LDL-
cholesterol should really be the marker/surrogate for clinical
outcomes [58]. There is also some evidence that short-term
treatment with ezetimibe increases small dense LDL-
cholesterol, which is associated with increased risk. Thus, ezeti-
mibe alone or in the presence of statins, has been shown to
increase the amounts of the pro-atherogenic small dense
LDLs [59,60]. Thus, long-term studies of the effects of ezetimibe
on LDL-cholesterol subfractions are indicated to determine
whether it is having a beneficial effect on this surrogate.
A large outcome trial is in progress to determine the clinical
outcomes with ezetimibe in the presence of simvastatin; the
IMPROVE-IT (Examining Outcomes in Subjects With
Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin)
vs Simvastatin trial) [61]. Enrolment for IMPROVE-IT has
stopped with 180,057 subjects after acute coronary syn-
dromes [62]. IMPROVE-IT will continue until 5250 subjects
have a primary end point event (death from cardiovascular
causes, myocardial infarction, hospital admission for unstable
angina, revascularization or stroke) [61,62]. The results from
IMPROVE-IT will not be known until 2015, and because
of the large number of primary end points required, may go
for longer, or be inconclusive [61,62]. It seems that the use of
ezetimibe in clinical practice should be discontinued or
stopped until the outcomes of IMPROVE-IT are known.
5.4 Effect of the combination of ezetimibe and
simvastatin versus placebo
In most of the clinical outcomes studies with the combination
of ezetimibe and simvastatin, the effects of the combination has
been compared with placebo. With this clinical trial design, it is
not possible to determine whether any differences between the
groups are due to simvastatin alone, ezetimibe alone, or the
combination of simvastatin and ezetimibe. Also, with the com-
bination, it is not possible to distinguish between beneficial and
detrimental effects, and the overall difference with placebo may
be a combination of these effects.
As there was a substantial decrease of LDL-cholesterol in
SEAS, the reduction of major ischaemic events was lower
with simvastatin/ezetimibe than might have been expected
with the use of statins alone as in the CTT meta-analysis of
14 statin trials [23]. However, when the subjects in SEAS
were divided into tertiles based on aortic jet velocity (as a
marker of asymptomatic aortic stenosis), the lipid-lowering
effect of the combination of simvastatin/ezetimibe gave a
comparable reduction in major ischaemic events to the
meta-analysis with the statins [23], for subjects with the least,
and middle aortic stenosis tertiles, but not in subjects with
the most severe aortic stenosis [63]. It seems to me that this
division into tertiles does not change the result that in
SEAS, the decrease in LDL-cholesterol with simvastatin/
ezetimibe gave a lesser decrease in major ischaemic events
than would be expected from the use of statins alone to reduce
the LDL-cholesterol to the same extent.
In SANDS, ezetimibe was also studied in the presence of a
statin (not specified), but the doses and statin uses were not
constant, and thus the LDL-cholesterol-lowering effects were
similar in the statin group and simvastatin/ezetimibe group [50].
In SANDS, there was no added benefit by adding the ezetimibe,
as the trial showed similar effects on carotid atherosclerosis in
subjects with type 2 diabetes with both regimens.
ARBITER 6-HALTS also showed no beneficial effect of
ezetimibe on carotid intima--media thickness in subjects
taking statins despite a reduction in LDL-cholesterol [39].
Interestingly, for a lesser reduction in LDL lowering when
niacin was added to the statins, there was a reduction in
the intima--media thickness [44]. This result also adds to the
accumulating evidence that ezetimibe may not have beneficial
effects on clinical outcomes.
S. A. Doggrell
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In kidney disease, simvastatin has not been studied alone in
SHARP, or (as per SA Doggrell’s knowledge) in any other
clinical trial, thus it is not know whether the effect of simva-
statin/ezetimibe is the effect of simvastatin, ezetimibe or the
combination. Atorvastatin has previously been shown to reduce
the risk of cardiac events in subjects with kidney disease and
type 2 diabetes undergoing dialysis in the 4D study [64].
Initially, rosuvastatin was not shown to decrease cardiovascular
events in subjects undergoing haemodialysis in the AURORA
(a study to evaluate the use of rosuvastatin in subjects on regular
haemodialysis: an assessment of survival and cardiovascular
events) which included both subjects with and without diabe-
tes [65]. However, a post hoc analysis of AURORA, which was
limited to the subjects with diabetes, showed that rosuvastatin
did reduce the risk of cardiac events [66]. Perhaps the beneficial
effect observed in SHARP was that of the simvastatin, and not
of the combination of ezetimibe and simvastatin. To test this,
ezetimibe needs to be compared with placebo, in subjects with
kidney disease taking simvastatin.
When target levels of LDL-cholesterol cannot be reached
with statins alone, ezetimibe is commonly added to the statin
to reduce the LDL-cholesterol (e.g., [3,67,68]). Also, the simva-
statin/ezetimibe combination is being proposed as an alternative
to atorvastatin and/or rosuvastatin (e.g., [69-71]). Is there any
point to this until it is known whether the LDL-cholesterol
lowering with ezetimibe improves clinical outcomes?
5.5 First, do no harm
The standard approach to any medical treatment is ‘first, do
no harm’. Simvastatin alone has beneficial effects on cardio-
vascular outcomes and long-term treatment is not associated
with any cancers [72]. By contrast, ezetimibe alone has not
been shown to have any beneficial effect on clinical cardiovas-
cular outcomes, but it may have some harmful effects. In
SEAS, cancer occurred more often in the simvastatin/ezeti-
mibe group (105 of 994 subjects, 11.1%) than in the placebo
group (70 of 929 subjects, 7.5%) [73]. However, there was no
evidence that any particular type of cancer was increased with
the simvastatin/ezetimibe combination [73]. In their discus-
sion, the authors point out that an increased risk of cancer
had not previously been reported with simvastatin, or with
ezetimibe in the SEAS trial, but this possible link between
ezetimibe and cancer needed to be further investigated [73].
This was further investigated by Peto et al. the effects of eze-
timibe on the risk of cancer in studies with larger numbers
of participants, namely SHARP and the ongoing
IMPROVE-IT trial [61,62], and suggested that there was no
credible evidence that ezetimibe increased the risk of cancer,
but that this needed longer follow-up [74]. However,
Petro et al. did report that in SHARP and IMPROVE-IT,
97 deaths from cancer have occurred in the ezetimibe group,
compared with 72 in the control group (p = 0.07), and that
when all three trials were combined, the death rates from
cancer were 134 versus 92 (p = 0.007), but argue that there
is bias in these data [73].
As discussed in Section 5.3, the study of West et al., in
subjects with peripheral arterial atherosclerosis, could be inter-
preted to mean that ezetimibe promotes the progression of
atherosclerosis. Until the long-term safety of ezetimibe is
established, regarding cancer and atherosclerosis, questions
must be asked about why it is being widely used.
5.6 Role of the pharmaceutical companies
As discussed above the effects of ezetimibe should have been
compared with placebo in subjects taking simvastatin, rather
than ezetimibe combined with simvastatin being compared
with placebo as was the case in VYCTOR [49], SEAS [53] and
SHARP [75]. The VYCTOR study was designed by the authors,
who were independent of the companies, but was partly funded
by Merck, Sharp & Dohme, Mexico [49]. SEAS was supported
by Merck and Schering-Plough Pharmaceuticals, who had two
members on the Steering committee, and acknowledges ‘the
work done by all Merck clinical research staff in facilitating
the study’ [53]. SHARP was supported by Merck and Schering
Plough Pharmaceuticals and national research bodies from
Australia and the UK, and the companies provided two non-
voting members to the Steering committee [75]. It is not clear
as to what was the role of the pharmaceutical companies in
the design of these trials, and why they funded trials comparing
the combination of simvastatin/ezetimibe against placebo.
What is apparent is that if these trials had been designed
correctly, that is, comparing ezetimibe with placebo in the pres-
ence of simvastatin, we would probably already know whether
ezetimibe had beneficial effects on clinical outcomes. The
results of the IMPROVE-IT trial are not due to 2015. One
of the consequences of this is that the ezetimibe/simvastatin
combination has been used for a long period, and earning a
large revenue for the companies, without the clinical data to
support the use. It is not clear why the drug regulatory bodies
have registered and supported the use of the ezetimibe/
simvastatin combination under these circumstances.
5.7 Conclusions
The comparison of clinical trials with simvastatin and ezeti-
mibe alone and together has clearly shown that simvastatin
decreases LDL-cholesterol and this is associated with
improved clinical outcomes. Also, ezetimibe alone or in the
presence of simvastatin lowers LDL-cholesterol. However,
ezetimibe alone or in the presence of simvastatin has not
been shown to have any irrefutable beneficial effects on
clinical outcomes. Thus, until/unless the use of ezetimibe is
clearly shown to improve clinical outcomes, its use should
be largely restricted to clinical trials investigating clinical
outcomes, and ezetimibe should not be used routinely in
everyday practice.
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